Cancers that overexpress a specific receptor that simultaneously exists on healthy cells make an ideal target for similar strategies, such as CD20 for B-cell lymphoma or CD30 for Hodgkin’s lymphoma. Here, TNFRSF8 is linked to B-cell non-Hodgkin lymphoma.